Through its pledge, BD will invest $19 billion in the U.S. over the span of “several years,” with the outlay taking the form of capital, operational and supply chain investments, the company said in ...

AbbVie and Genmab are touting a much-anticipated first-line win for | Epkinly plus R-CHOP cut the risk of progression or death by 51% compared with R-CHOP alone in newly diagnosed DLBCL, setting up a ...

As competition in both the HIV treatment and prevention fields continues to mount, GSK’s ViiV Healthcare is looking to expand ...

Already boasting a positive recommendation overseas, Novo’s hemophilia A newcomer Frehemgo will have to wait a while longer ...

Attruby maker BridgeBio is re-upping its “Don’t Pass on Your Heart Health” campaign with a fresh new beat.  | BridgeBio's YouTube awareness push to lead up to World Amyloidosis Day features a ...

The FDA has warned Evolus over an Instagram reel that made the “especially problematic” suggestion of blurred lines between a ...

Just weeks after IntraBio secured a label expansion for its lead asset Aqneursa, Japanese drugmaker Shionogi is moving in to ...

Eli Lilly’s Jaypirca, the first noncovalent BTK inhibitor, has won FDA approval for the first-line treatment of chronic ...

Following a spate of large-scale pharma investments in the U.S. last year, German conglomerate Bayer is advancing its own plans to expand in America, in a move the company is framing as the ...

While Foundayo’s insulin-matching potential in type 2 diabetes had been established in a topline readout earlier this year, ...

INS is Gazyva’s second immune-mediated indication, following an approval last October in adult lupus nephritis, a potentially ...

Genentech is turning up the volume on breast cancer conversations in its “About Damn Time” campaign with Breastcancer.org and ...